WAVE Life Sciences Continues Development of Two Drug Therapies for Huntington’s
May 16, 2017 12:46 pm | Joana Fernandes, PhD
WAVE Life Sciences’ products WVE-120101 (SNP-1) and WVE-120102 (SNP-2) will enter clinical trials in mid-2017 as part of the effort to develop new treatments for patients with Huntington’s disease. “2017 will be an important year for WAVE as we transition our two lead candidates in Huntington’s disease … into clinical trials,” Paul Bolno, MD, and […]
The post WAVE Life Sciences Continues Development of Two Drug Therapies for Huntington’s appeared first on Huntington's Disease News. |
A team of researchers has discovered new insights into cell processes that have gone awry in Huntingon’s disease (HD) patients. This discovery could point scientists toward a potential method of interfering with those processes. The study, “KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington’s disease patients,” was published in the journal Proceedings […]
Researchers at the Sussex Drug Discovery Centre in Brighton, England, have received a £3 million grant from Britain’s non-profit Wellcome Trust to develop Huntington’s disease treatments. The team will team up with other researchers to target a protein that plays a role in cognitive impairment, one of the hallmarks of the neurological disease. The grant is equivalent to $3.37 […]
Researchers have discovered why Huntington’s disease (HD) patients have defects in the blood-brain barrier that contribute to the symptoms of this neurological disorder. Their study, “Huntington’s Disease iPSC-Derived Brain Microvascular Endothelial Cells Reveal WNT-Mediated Angiogenic and Blood-Brain Barrier Deficits,” was published in Cell Reports. “Now we know there are internal problems with blood vessels in the […]
WAVE Life Sciences’ products WVE-120101 (SNP-1) and WVE-120102 (SNP-2) will enter clinical trials in mid-2017 as part of the effort to develop new treatments for patients with Huntington’s disease. “2017 will be an important year for WAVE as we transition our two lead candidates in Huntington’s disease … into clinical trials,” Paul Bolno, MD, and […]